Record revenues and a $32.50 price target make BSEM a hot biotech stock for your 2025 radar! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts. The #1 biotech stock to watch in 2025 With a grand $32.50 price target from Zack’s SCR and record breaking revenues in 2024, 2025 could be another epic breakout year for BSEM! BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. This little-known biotech company has generated record revenues in 2024 and has been dubbed a company to watch by Zack’s Small Cap Research! In Q3 2024, the company posted revenue of $82.6 million for the quarter, totaling $199 million for the first nine-months of 2024. Following BSEM’s Q3 results, Zack’s Small Cap Research increased its price target from $24.25 to $32.50! A recent study has confirmed that BSEM technology is superior and very helpful to patients. As more doctors turn to BioStem for treatments, resulting in increasing sales, 2025 could be another year of jaw dropping revenues. Especially as the company is anticipating to uplist to the NASDAQ! BioStem Technologies Inc. (OTC: BSEM) has additionally achieved another major milestone by wrapping up 2024 with a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global LLC, a pioneering medical device company leveraging cutting-edge advances in biomaterials to provide effective, affordable advanced wound care solutions. The acquisition of ProgenaMatrix and revyve Antimicrobial Wound Gel reflects the Company’s continued commitment to building a diverse portfolio of complementary wound care products that enable BioStem to leverage its commercial infrastructure. See how an anticipated NASDAQ uplisting and strong quarterly results are positioning BSEM for another potential epic run in 2025! | Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $2,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 2/13/2025. Behind the Markets Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today's Bonus Content: 5 Stocks Under $5 with Big Potential (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time.) | |